Diagnostic and therapeutic tools for idiopathic pulmonary fibrosis: the potential and challenges of blood biomarkers
10.3760/cma.j.cn114452-20231109-00266
- VernacularTitle:特发性肺纤维化的诊疗工具：血液生物标志物的潜力与挑战
- Author:
Hongxia RUAN
1
;
Jie CHEN
Author Information
1. 四川大学华西医院实验医学科，成都 610041
- Keywords:
Pulmonary fibrosis;
Biomarkers;
Blood;
Clinical application
- From:
Chinese Journal of Laboratory Medicine
2024;47(10):1115-1122
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic pulmonary fibrosis (IPF), the most common form of pulmonary fibrosis, is a chronic progressive interstitial lung disease characterized by rapid progression, irreversibility, and poor prognosis. The median survival of diagnosed patients is only 3 to 5 years, so timely diagnosis and accurate evaluation are essential for controlling the disease, improving patient outcomes, and prolonging survival years. The main methods of diagnosing IPF in clinical practice include clinical evaluation, imaging examination, and pathological biopsy. However, there are still challenges in clinical application as they rely heavily on the clinical expertise of physicians, involve invasive procedures, and can be cumbersome. The rapid development of medicine has led to the discovery of various blood biomarkers closely associated with the pathogenesis of IPF. These biomarkers are crucial reference and foundation for establishing clinical laboratory diagnosis, differential diagnosis, prognosis, and efficacy assessment methods for IPF.
